Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6110636 | Pancreatology | 2016 | 17 Pages |
Abstract
Recent studies confirm that patients with chronic pancreatitis receive similar benefit from pancreatic exocrine replacement therapy (PERT) to that established in children with cystic fibrosis. Severe acute pancreatitis is frequently followed by PEI and PERT should be considered for these patients because of their nutritional requirements. Evidence is also becoming stronger for the benefits of PERT in patients with unresectable pancreatic cancer. However there is as yet no clear guide to help identify those patients in the 'unlikely' PEI group who would benefit from PERT. For example, patients with coeliac disease, diabetes mellitus, irritable bowel syndrome and weight loss in the elderly may occasionally be given a trial of PERT, but determining its effectiveness will be difficult. The starting dose of PERT should be from 25,000-40,000 IU lipase taken with food. This may need to be titrated up and there may be a need for proton pump inhibitors in some patients to improve efficacy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Working Party of the Australasian Pancreatic Club: Working Party of the Australasian Pancreatic Club:, Ross C. Smith, Sarah F. Smith, Jeremy Wilson, Callum Pearce, Nick Wray, Ruth Vo, John Chen, Chee Y. Ooi, Mark Oliver, Tamarah Katz, Richard Turner,